Different strategies have been developed to inhibit the MET signaling pathway in NSCLC, including MET TKIs, HGF antagonists (such as rilotumumab [AMG-102] and ficlatuzumab [AV-299]), and anti-MET monoclonal antibodies (such as onartuzumab and emibetuzumab). This evidence concerns the gene MET and non-small cell lung carcinoma.